NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

After BioNTech’s acquisition of CureVac closes, BioNTech will pay GSK another $130 million and a 1% royalty on rest-of-world ...

Q1 2025 Management View CEO Matthew Gline described the quarter as "relatively quiet" ahead of an "exciting, busy fall," ...

Kennedy is vowing to "fix" the federal program for compensating Americans injured by vaccines, opening the door to sweeping changes for a system long targeted by anti-vaccine activists.

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage.